Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Breast Cancer
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The role of epigenetic regulators and their dysregulation in cancer have gained much attention recently, as they influence the gene expression of many oncogenes and tumor suppressor genes. Non-coding RNAs (ncRNAs) including (lncRNAs and miRNAs) and chromatin remodeling machinery proteins are key epigenetic regulators playing a key role in carcinogenesis. In addition, they can serve as diagnostic and prognostic markers in many cancer types including breast cancer. Therefore, studying these molecular markers will help in the diagnosis and prognosis as well as in the better understanding of this devastating disease.To the best of our knowledge, This is the first research work measuring the expression level of UPK1A-AS1 and/or UNC5B-AS1 in breast cancer clinical samples. These data could provide a promising approach in introducing a novel markers that help in the diagnosis and prognosis of breast cancer and provide a potential targets for gene therapy.

Design

Study type: Observational Observational model: Case Control Time perspective: Retrospective

Primary Outcomes

  • Elucidate the role of our candidate lncRNAs and their downstream targets obtained from breast cancer patients' liquid biopsy and/or tissue samples. (around 12 months)
  • Compare the expression level of lncRNA UPK1A- AS1 and/or UNC5B-AS1 and their target miRNAs in serum samples (liquid biopsy) and/or tissue samples from breast cancer patients, using (qRT-PCR) to their expression in healthy volunteers (around 12 months)
  • Compare serum and/or tissue target proteins level, by ELISA to their levels in healthy volunteers. (around 12 months)
  • Correlate these ncRNAs and target protein level axis, to the clinicopathological characteristics of breast cancer (around 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-11-23
Completion: 2025-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ain Shams University
Principal Investigators:
  • Sherihan Galal, phD (PRINCIPAL_INVESTIGATOR) - Ain Shams University
Contact Information
Study Contact:
Sherihan Galal, phD
01022850699
Dr.sherehan@pharma.asu.edu.eg
Sherihan Galal, phD
01022850699
Dr.sherehan@pharma.asu.edu.eg
Faculty of pharmacy, Ain Shams University
Sherihan Galal, phD
Faculty of pharmacy, Ain Shams University
Interventions
N/A
Study Locations (1 sites)
Faculty of pharmacy, Ain Shams University, Cairo, Egypt
Eligibility Criteria
Inclusion Criteria: Egyptian females breast cancer patients aged 18 years and above, newly diagnosed with breast cancer. Exclusion Criteria: Blood diseases, any cancer other than breast cancer, liver cirrhosis and uterine and urinary bladder diseases or breast cancer patients with any evidence of distant metastases.
Conditions Breast Neoplasm Female, Radiotherapy, Co...
Phase PHASE3
Enrollment 910
Locations 31 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The primary objective of this study is to determine in women with node negative BC ≤3cm in size, if PBI compared to WBI, both given once-a-day over 1 week following BCS, is non-inferior for LR and reduces adverse cosmesis. The primary outcomes are LR and patient-assessed cosmesis at 3 years post randomization.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Radiation: Whole Breast Irradiation (WBI) — The dose fractionation and prescription is 26Gy in 5 fractions to the PTV once per day over 5-7 days (due to holiday weekends up to 8 days will be acceptable).
  • Radiation: Partial Breast Irradiation (PBI) — The dose fractionation and prescription is 26Gy in 5 fractions to the PTV prescribed at the isocentre of the treatment fields treated once per day over 5-7 days (due to holiday weekends up to 8 days will be acceptable).

Primary Outcomes

  • Local Recurrence (Annually for 5 years post-randomization)
  • Patient Assessment Cosmesis at 3 years (3 and 5 years post-randomization)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-11-20
Completion: 2031-11
Eligibility
Age: 50 Years – 120 Years
Sex: FEMALE
Volunteers: false
Enrollment: 910 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ontario Clinical Oncology Group (OCOG)
Collaborators: Canadian Institutes of Health Research (CIHR)
Principal Investigators:
  • Timothy Whelan, M.D. (PRINCIPAL_INVESTIGATOR) - Juravinski Cancer Centre and McMaster University
Contact Information
Study Contact:
Shelley Chambers, MA
905-527-2299
schamber@mcmaster.ca
Erin McGean
905-527-2299
mcgeane@mcmaster.ca
Katerina Zavitsanou
katerina.zavitsanou@genesiscare.com
GenesisCare Darlinghurst
Interventions
  • Radiation: Whole Breast Irradiation (WBI) — The dose fractionation and prescription is 26Gy in 5 fractions to the PTV once per day over 5-7 days (due to holiday weekends up to 8 days will be acceptable).
  • Radiation: Partial Breast Irradiation (PBI) — The dose fractionation and prescription is 26Gy in 5 fractions to the PTV prescribed at the isocentre of the treatment fields treated once per day over 5-7 days (due to holiday weekends up to 8 days will be acceptable).
Study Locations (31 sites)
GenesisCare Darlinghurst, Darlinghurst, New South Wales 2010 Australia
GenesisCare Hurstville, Hurstville, New South Wales 2220 Australia
GenesisCare Mater Hospital, North Sydney, New South Wales 2060 Australia
GenesisCare Bundaberg, Bundaberg, Queensland 4670 Australia
GenesisCare Southport, Southport, Queensland 4215 Australia
GenesisCare Tugun, Tugun, Queensland 4224 Australia
GenesisCare Hervey Bay, Urraween, Queensland 4655 Australia
GenesisCare St Andrew's, Adelaide, South Australia 5000 Australia
GenesisCare Bedford Park, Bedford Park, South Australia 5042 Australia
GenesisCare Wembley, Wembley, Washington 6014 Australia
Eligibility Criteria
Inclusion Criteria: For inclusion in this study, patients must fulfill all of the following criteria: 1. Female with a new histological diagnosis of invasive carcinoma of the breast with no evidence of metastatic disease (see AJCC TNM Cancer Staging, Appendix II). 2. Treated by BCS with microscopically clear resection margins \>= 1mm for invasive and non-invasive disease or no residual disease on re-excision. 3. Negative axillary node involvement as determined by either sentinel lymph node biopsy or axillary node dissection or clinical assessment with a negative axillary ultrasound and/or biopsy, for women with unifocal tumours \<= 2cm, histologic grade 1 or 2, ER or PR+ and HER2-ve that are being planned for endocrine therapy Exclusion Criteria: Patients who satisfy any of the following exclusion criteria are NOT eligible for this study: 1. Age less than 50 years. 2. Known to be BRCA 1 and/or BRCA 2 positive. 3. Tumour size \>3cm in greatest diameter on pathological examination. 4. Evidence of extensive intraductal component (EIC) (defined as an invasive tumour with a ductal carcinoma in situ (DCIS) component comprising at least 25% and extending beyond the invasive component to surrounding normal breast tissue) with the following exception: smaller tumours with EIC where the combined size (of the invasive and DCIS components) are \<= 3cm remain eligible 5. Evidence of a DCIS component \> 3cm 6. Lobular carcinoma only. 7. More than one primary tumour in different quadrants of the same breast (patients with multifocal breast cancer are eligible). 8. Synchronous or previous contralateral breast cancer (patients with contralateral DCIS or LCIS are eligible). 9. History of non-breast malignancy within the last 5 years other than treated non-melanoma skin cancer or treated in-situ carcinoma. 10. Known pregnancy or currently lactating. 11. Inability to localize tumour bed on CT planning (no evidence of surgical clips or seroma). 12. Inability to plan the patient for the experimental technique.
Conditions HR+/HER2- Breast Cancer
Phase PHASE2
Enrollment 30
Locations 11 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

This study is a prospective, single arm, multi-center phase II clinical trial. The primary study objective is to evaluate the pathologic complete response(PCR)and RCB0-1 ratio of neodjuvant treatment of HR+/HER2- breast cancer with Toripalimab combined with neoadjuvant chemotherapy and sequential Toripalimab monoclonal antibody, including the incidences and types of adverse events. The secondary study objective is to observe and evaluate the disease-free survival (DFS), Progression-Free-Survival (PFS ),and Objective Response Rate(ORR)

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Neoadjuvant Chemotherapy in Combination with Toripalimab — Epirubicin (or Liposomal Doxorubicin)+Cyclophosphamide, intravenous infusion of 100 mg/m2. Epirubicin (or 35 mg/m2 liposomal doxorubicin)+600 mg/m2 cyclophosphamide, starting from the first day of the week, for a total of 12 weeks. Paclitaxel, administered intravenously at a dose of 260 mg/m2 every 3 weeks for a total of 12 weeks. During neoadjuvant chemotherapy and postoperative adjuvant therapy, use of Toripalimab: intravenous infusion of 240 mg, once every 3 weeks, combined with preoperative neoadjuvant and postoperative adjuvant therapy for a total of 1 year.
  • Drug: HR+ HER2 breast cancer — During neoadjuvant chemotherapy and postoperative adjuvant therapy, use of Toripalimab: intravenous infusion of 240 mg, once every 3 weeks, combined with preoperative neoadjuvant therapy and postoperative adjuvant therapy for a total of 1 year.

Primary Outcomes

  • pathologic complete response(PCR) (2 years)
  • RCB 0-1 Ratio (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-06-11
Completion: 2029-06
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: First Affiliated Hospital of Zhejiang University
Principal Investigators:
  • Guansheng Sheng (PRINCIPAL_INVESTIGATOR) - Zhejiang University
Contact Information
Study Contact:
Zhijun Dai
+86 157 0581 9132
dzj0911@126.com
Youyi Chen
+86 157 5751 5017
Zhijun Dai
The First Affiliated Hospital of Zhejiang University
Interventions
  • Drug: Neoadjuvant Chemotherapy in Combination with Toripalimab — Epirubicin (or Liposomal Doxorubicin)+Cyclophosphamide, intravenous infusion of 100 mg/m2. Epirubicin (or 35 mg/m2 liposomal doxorubicin)+600 mg/m2 cyclophosphamide, starting from the first day of the week, for a total of 12 weeks. Paclitaxel, administered intravenously at a dose of 260 mg/m2 every 3 weeks for a total of 12 weeks. During neoadjuvant chemotherapy and postoperative adjuvant therapy, use of Toripalimab: intravenous infusion of 240 mg, once every 3 weeks, combined with preoperative neoadjuvant and postoperative adjuvant therapy for a total of 1 year.
  • Drug: HR+ HER2 breast cancer — During neoadjuvant chemotherapy and postoperative adjuvant therapy, use of Toripalimab: intravenous infusion of 240 mg, once every 3 weeks, combined with preoperative neoadjuvant therapy and postoperative adjuvant therapy for a total of 1 year.
Study Locations (11 sites)
The First Affiliated Hospital of Zhejiang University, Hangzhou, China
Zhejiang Cancer Hospital, Hangzhou, China
Harbin Medical University Cancer Hospital, Harbin, China
The First Affiliated Hospital of Anhui Medical University, Hefei, China
Jinhua Municipal Central Hospital, Jinhua, China
Nanchang People&#39;s Hospital, Nanchang, China
Zhongshan Hospital, Fudan University, Shanghai, China
Xinjiang Medical University Affiliated Cancer Hospital, Ürümqi, China
Shaanxi Provincial Cancer Hospital, Xi'an, China
The Second Affiliated Hospital of Xi&#39;an Jiaotong University, Xi'an, China
Eligibility Criteria
Inclusion Criteria: 1. Female patients aged 18-75 years old; 2. ECOG score is 0-1 points; 3. breast cancer meets the following standards: Histologically confirmed invasive breast cancer with tumor diameter\&gt;1cm (T1c-3; N0-3; M0). All patients were pathohistologically confirmed as HR+/HER2- breast cancer. According to the breast cancer diagnosis and treatment guidelines and specifications of the Chinese Anti Cancer Association (2021 version), Luminal B is divided into Luminal B (HER2 negative) and Luminal B (HER2 positive). Luminal B (HER2 negative) is ER/PR positive, HER2 negative and Ki-67 proliferation index is high or PR low expression. Luminal type B (HER2 positive) is ER/PR positive, HER2 positive (protein overexpression or gene amplification), and Ki-67 in any state. Therefore, HR+/HER2- breast cancer is a Luminal type breast cancer patient excluding HER2+. Pathological examination of PD-L1 expression: The Combined Positive Score (CPS) refers to the percentage of PD-L1 positive cells (including tumor cells, lymphocytes, macrophages) in all tumor cells. Our center detected the PD-L1 antibody site as 22C3. 4. The functional level of major organs must meet the following requirements (no blood transfusion within 2 weeks before screening, no use of...) Using leukocyte and platelet boosting drugs: 1. Blood routine: Absolute neutrophil count (ANC) greater than 1.5 × 109/L; platelet count (PLT) greater than 75 × 109/L; Hemoglobin (Hb) is greater than 90g/L; Lymphocyte count ≥ 1.5 × 109/L 2. Blood biochemistry: Total bilirubin (TBIL) is less than 1.5 × ULN; Alanine aminotransferase ALT and aspartate levels are less than 1.5 × ULN; Alkaline phosphatase is less than 2.5 × ULN; Urea nitrogen/ Urea (BUN/UREA) and creatinine (Cr) are less than 1.5 × ULN. 3. Cardiac ultrasound: Left ventricular ejection fraction (LVEF) greater than 55%. 4. 12 lead electrocardiogram: The Fridericia corrected QT interval (QTcF) is less than 470 milliseconds 5. For female patients who have not yet reached menopause or undergone surgical sterilization: during the treatment period and in the study treatment, the final use effective contraceptive methods for at least 6 months after a single administration. 6\. Voluntarily join this study, sign an informed consent form, have good compliance, and are willing to cooperate with follow-up. Exclusion Criteria: 1. Stage IV breast cancer. 2. Inflammatory breast cancer. 3. Previously received anti-tumor treatment or radiation therapy for any malignant tumor, excluding those that have been cured Malignant tumors such as cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma. 4. Simultaneously undergoing anti-tumor treatment in other clinical trials, including but not limited to chemotherapy and endocrine therapy. Treatment, biological therapy, bone improvement drug therapy, or immune checkpoint inhibitor therapy, etc. 5. The patient had undergone major surgical procedures unrelated to breast cancer within 4 weeks before the first administration of the study drug, or the patient has not fully recovered from such surgical procedures. 6. Serious heart disease or discomfort, including but not limited to the following diseases: 1\) Diagnosed history of heart failure or systolic dysfunction (LVEF less than 50%). 2\) High risk uncontrolled arrhythmias, such as atrial tachycardia, resting heart rate greater than 100bpm, significant ventricular arrhythmias (such as ventricular tachycardia), or higher-level atrioventricular block (i.e. Mobitz II second or third degree atrioventricular block). 3\) Angina requiring medication for treatment. 4) Heart valve disease with clinical significance. 5) ECG shows transmural myocardial infarction. 6) Poor control of hypertension (systolic blood pressure greater than 180mmHg and/or diastolic blood pressure greater than 180mmHg after drug treatment) 100mmHg). 7. Uncontrolled active infections that require treatment; History of immunodeficiency, including HIV testing positive Sexual, or suffering from other acquired or congenital immunodeficiency diseases, or having a history of organ transplantation. 8\. Patients with chronic active hepatitis B or active hepatitis C (excluding hepatitis B virus carriers, stable hepatitis B after drug treatment \[HBV-DNA test negative or\&lt;50IU/ml\] and cured hepatitis C patients \[HCV RNA test negative\]). 9\. Have received immunotherapy and experienced adverse immune events such as immune related pneumonia and myocarditis, which have been determined by researchers to potentially affect the safety of the experimental medication. 10\. Individuals with a known history of allergies to the components of this medication regimen. 11\. Pregnant and lactating female patients, female patients with fertility and positive baseline pregnancy test results, or reproductive age patients who are unwilling to take effective contraceptive measures during the entire trial period and within 6 months after the last study medication. 12\. Suffering from serious accompanying diseases or other comorbidities that may interfere with the planned treatment, or any other circumstances that the researcher deems unsuitable for the patient to participate in this study.
Conditions Anatomic Stage I Breast Cancer AJCC v8, ...
Phase PHASE1
Enrollment 18
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

This phase I trial tests the safety, side effects, and best dose of a personalized vaccine (tumor membrane vesicle or TMV vaccine) by itself and in combination with checkpoint inhibitor (pembrolizumab or ipilimumab) in treating patients with triple negative breast cancer. This vaccine is made by taking a piece of patient's triple negative breast cancer to design a vaccine to stimulate the immune system's memory. Patients are treated with the personalized vaccine immunotherapy with or without monoclonal antibodies, such as pembrolizumab and ipilimumab. This approach may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving personalized TMV vaccine with pembrolizumab or ipilimumab may help the immune system attack cancer better and reduce the risk of this breast cancer coming back or growing.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: Ipilimumab — Given IV
  • Biological: Pembrolizumab — Given IV
  • Biological: Vaccine Therapy — Given TMV vaccine ID

Primary Outcomes

  • Incidence of adverse events (Phase Ia) (Up to 2 years)
  • Dose limiting toxicity (Phase Ia) (Up to week 5)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-12-02
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 18 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Emory University
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Keerthi Gogineni, MD, MSHP (PRINCIPAL_INVESTIGATOR) - Emory University Hospital/Winship Cancer Institute
Contact Information
Study Contact:
Keerthi Gogineni, MD, MSHP
404-778-1900
keerthi.gogineni@emory.edu
Deborah Omoyege
deborah.omoyege@emory.edu
Grady Health System
Keerthi Gogineni, MD, MSHP
Grady Health System
Interventions
  • Biological: Ipilimumab — Given IV
  • Biological: Pembrolizumab — Given IV
  • Biological: Vaccine Therapy — Given TMV vaccine ID
Study Locations (4 sites)
Grady Health System, Atlanta, Georgia 30303 United States
Emory University Hospital Midtown, Atlanta, Georgia 30308 United States
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia 30322 United States
Emory Saint Joseph's Hospital, Atlanta, Georgia 30342 United States
Eligibility Criteria
Inclusion Criteria: * Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information * Must be age \>= 18 years * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 14 days prior to tissue consent * Absolute neutrophil count \> 1500/mcL (obtained within 14 days prior to vaccine administration) * Absolute lymphocyte count \>= 600 cells/µl (obtained within 14 days prior to vaccine administration) * Platelets \> 100,000 mm (obtained within 14 days prior to vaccine administration) * Hemoglobin \> 9.0 g/dL (obtained within 14 days prior to vaccine administration) (NOTE: The use of transfusion or other intervention to achieve hemoglobin \[Hgb\] \> 9.0g/dl is acceptable) * Serum creatinine =\< 1.5 x upper limit of normal (ULN) or calculated creatinine clearance \>= 60 mL/min using Cockcroft-Gault equation for patients with creatinine levels \> 1.5 x institutional ULN (obtained within 14 days prior to vaccine administration) * Total bilirubin =\< 1.5 x ULN OR direct bilirubin =\< 1 x ULN (obtained within 14 days prior to vaccine administration) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 x ULN unless liver metastases are present, in which case they must be =\< 5 x ULN (obtained within 14 days prior to vaccine administration) * Bilirubin =\< 1.5 X ULN (except in participants with documented Gilbert's disease, who must have a total bilirubin =\< 3.0 mg/dL) (obtained within 14 days prior to vaccine administration) * International normalized ratio (INR) or prothrombin time (PT) =\< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants (obtained within 14 days prior to vaccine administration) * Activated partial thromboplastin time (aPTT) =\< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants (obtained within 14 days prior to vaccine administration) * TNBC as defined by estrogen receptor (ER)/progesterone receptor (PR) =\< 10% if Allred =\< 3; Her2/neu negative as defined by scores of 0 or 1+ by immunohistochemistry (IHC) or 2+ by IHC associated with a fluorescence in situ hybridization (FISH) ratio of \< 2.0 or \< 6 Her2 copies per cell * Patients with metastatic or inoperable locally advanced disease: Metastatic or inoperable locally advanced disease is defined as either histologically confirmed metastatic breast cancer by biopsy; or locally advanced breast cancer that, in the opinion of the treating physician, is not amenable to curative intent surgical resection; or, radiological or clinical evidence suggestive and supportive of metastatic disease * Documented metastatic biopsy is not required provided the patient has a prior diagnosis of TNBC that otherwise meets the eligibility criteria * Eligible patients must have =\< 3 lines of chemotherapy in the metastatic/advanced disease setting. For patients who have relapsed within 6 months of systemic therapy given within curative intent, that therapy will count as a line of metastatic therapy. Last cycle of cytotoxic therapy must be \>= 21 days prior to cycle (C)1 day (D)1 of vaccine. Last cycle of checkpoint inhibitor therapy be \>= 28 days prior to C1D1 of vaccine. Last dose of radiotherapy must be \>= 14 days prior to C1D1 of vaccine * Prior checkpoint inhibitor is permitted. Patients who are known to have PD-L1 positive with combined positive score (CPS) \>= 10 will be required to have had pembrolizumab therapy prior to enrollment * Patients who are metastatic or inoperable, locally advanced will only be eligible for the Phase 1b combination cohort. They will not be eligible for the Phase 1a dose escalation cohort. Patients who have received prior anti-CTLA-4 antibody will preferentially be enrolled to cohort B (combination of TMV vaccine with pembrolizumab). Patients who have received prior PD-L1 or PD-1 antibody therapy will preferentially be enrolled to cohort C (combination of TMV vaccine with ipilimumab). Patients with metastatic disease who have received no prior immune checkpoint inhibitor therapy will be assigned to a treatment arm based on available slots and discretion of treating physician * Patients with early stage TNBC: Early stage TNBC is defined as clinical or pathologic Stage I-III TNBC * After resection of disease in the breast and axilla, early stage patients are eligible for either the Phase 1a dose escalation of TMV vaccine monotherapy Cohort A or the Phase 1b combination arm of the vaccine with immune checkpoint inhibitor (ICI) * Patients will be required to have completed adjuvant radiotherapy (if indicated) \>= 14 days prior to initiation of vaccine on trial * Patients who have residual disease after completion neoadjuvant therapy that proceed with adjuvant capecitabine can enroll \>= 28 days after completion of final dose of capecitabine. Patients electing to enroll onto the Phase 1a Cohort A monotherapy arm can enroll prior to initiation of capecitabine, however must not initiate capecitabine prior to the Week 12 blood draw (measurement of immune biomarkers) on study * Patients who have a germline BRCA 1/2 mutation that meet the Food and Drug Administration (FDA) indication for use of adjuvant Olaparib can enroll \>= 28 days after completion of final dose of olaparib. Patients electing to enroll onto the Phase 1a Cohort A monotherapy arm can enroll prior to initiation of olaparib, however must not initiate olaparib prior to the Week 12 blood draw (measurement of immune biomarkers) on study * Patients who undergo upfront surgery: Patients may initiate injection of vaccine \>= 28 days after completion of final cycle of adjuvant chemotherapy * Patients who have early stage breast cancer that have residual disease after completing neoadjuvant chemotherapy with the KEYNOTE 522 regimen (pembrolizumab at a dose of 200 mg every 3 weeks plus weekly paclitaxel and carboplatin for 4 cycles followed by pembrolizumab-doxorubicin-cyclophosphamide or of pembrolizumab-epirubicin-cyclophosphamide every 3 weeks for 4 cycles): * Patient enrolling onto Phase 1a Cohort A will initiate injection of vaccine \>= 28 days after completion of final cycle of standard of care adjuvant pembrolizumab * Patient enrolling onto Phase 1b Cohort B or C will initiate injection of vaccine \>= 28 days surgical resection. Patients who have received pembrolizumab as part of the preoperative KEYNOTE 522 regimen will preferentially be enrolled to cohort B (combination of TMV vaccine with pembrolizumab) and will receive up to 9 cycles of adjuvant pembrolizumab every 3 weeks as per standard of care. Vaccine will be administered every 2 weeks for 3 doses prior to the first three ICI cycles * Patients who have early stage breast cancer that have that have residual disease after completing neoadjuvant chemotherapy with either dose-dense doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel-cyclophosphamide: * Patient enrolling onto Phase 1a Cohort A will initiate injection of vaccine \>= 28 days surgical resection * Patient enrolling onto Phase 1b Cohort B or C will initiate injection of vaccine \>= 28 days surgical resection. Patients will be assigned to receive either pembrolizumab (Cohort B) every 3 weeks for 6 cycles or ipilimumab (Cohort C) every 3 weeks for 4 cycles in combination with TMV vaccine based on available slots in each arm and discretion of treating physician. Vaccine will be administered every 2 weeks for 3 doses; the TMV vaccine will be administered prior to the ICI cycle if ICI is due. * Weight of tumor tissue for production of vaccine must be at least 1 gram. In metastatic patients, preferentially, invasive tumor in breast or lymph node tissue will be retrieved by excisional biopsy to ensure sufficient yiel

The Florida ASCENT Study

NCT07042243
Recruiting
Conditions Cancer, Food Deprivation, Food Habits, F...
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to adapt, implement, and evaluate MyCarePulse and ASCENT patient navigator to overcome barriers to care among patients with cancer. The main hypotheses it aims to test are: * At the patient level, the intervention will result in higher levels of food security, self- efficacy for dietary behaviors, and higher diet quality than standard care. * At the provider level, the intervention will be feasible, acceptable, appropriate, and able to enhance individualized care for patient wellness. Researchers will compare cancer patients receiving the MyCarePulse and ASCENT patient navigator intervention to those receiving standard care, to see if the intervention improves food security, self-efficacy, and diet quality. Phase 1 Patient Participants will: * Complete the ASCENT Questionnaire, which is comprised of the following: * U.S. Food Security Survey Module (U.S. FSSM) * Patient-Reported Outcomes Measurement Information System (PROMIS-29) * General Self-Efficacy Scale (GSE) * Complete the Automated Self-Administered 24-Hour (ASA24®) Dietary Assessment Tool a total of 4 times. * Be assessed using the Veggie Meter instrument * Participate in two semi-structured interviews Provider Participants will: •Participate in one semi-structured interview Phase 2 Patient Participants will: * Participate in ASCENT patient navigator screenings and consultations * Complete the ASCENT Questionnaire, which comprises the U.S. FSSM, PROMIS-29, and ASA24®

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Behavioral: MyCarePulse and ASCENT PN — The combination of a digital platform and patient navigators assisting the process. Also, taking a multi-level approach engaging community members, patients, and providers in phase one through qualitative interviews. Then using the findings to adapt MyCarePulse for the clincial trial in phase two.

Primary Outcomes

  • Change in Food security from Baseline using U.S. FSSM (6 months)
  • Change in Diet quality from Baseline using the ASA24 Dietary Recall Assessment and the Veggie Meter Instrument (6 months)
  • Change in Self efficacy for dietary behaviors from Baseline using the the Preferences and Self-Efficacy of Diet and Physical Activity Behaviors Scale (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-05
Completion: 2027-08
Eligibility
Age: 18 Years – 100 Years
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Florida
Collaborators: University of Miami
Contact Information
Study Contact:
Dejana Braithwaite, PhD, MSc
4152165093
dbraithwaite@surgery.ufl.edu
Interventions
  • Behavioral: MyCarePulse and ASCENT PN — The combination of a digital platform and patient navigators assisting the process. Also, taking a multi-level approach engaging community members, patients, and providers in phase one through qualitative interviews. Then using the findings to adapt MyCarePulse for the clincial trial in phase two.
Study Locations (1 sites)
University of Florida, Gainesville, Florida 32610 United States
Eligibility Criteria
Patient Eligibility Inclusion Criteria: 1. ≥18 years old. 2. Pathologically confirmed diagnosis, with a focus on, but not limited to, colorectal, prostate, lung, breast, gynecologic, hematologic, or skin (including melanoma) cancers. 3. Self-reported ability to read and speak English. 4. Able to provide informed consent. Patient Eligibility Exclusion Criteria: 1. ≤18 years old. 2. Does not have a pathologically confirmed diagnosis of cancer. 3. Currently receiving active cancer treatment (e.g., active chemotherapy, radiation therapy or stem cell transplant); patients on stable maintenance therapy are eligible (e.g., endocrine therapy, targeted therapy, or select immunotherapy). 3\) Does not live within the state of Florida. 3) Does not self-reported ability to read and speak English or Spanish. 4) Not able to provide informed consent. Provider Eligibility Inclusion Criteria 1. ≥18 years old. 2. Currently works as a physician, physician assistant, patient navigator and/or health system/administrative leader in UF and UM affiliated clinics. 3. Self-reported ability to read and speak English or Spanish. 4. Able to provide informed consent. Provider Eligibility Exclusion Criteria 1. ≤ 18 years old. 2. Does not currently works as a physician, physician assistant, patient navigator and/or health system/administrative leader in UF and UM affiliated clinics. 3. Does not self-report having the ability to read and speak English. 4. Not able to provide informed consent.
Conditions Ovarian Cancer, Breast Cancer, Lung Canc...
Phase NA
Enrollment 625
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer diagnoses will be enrolled across up to 8 clinical sites to participate in a randomized wait-list control study. Those in the intervention group will receive 6 months of digital coaching up front followed by 6 months of ongoing monitoring via patient reported and clinical outcomes, as well as wearable data. Those in the control group will be monitored via patient reported and clinical outcomes as well as wearable data for the first 6 months followed by 6 months of digital health coaching. Both groups will collect fecal microbiome samples at enrollment and month 6. The study aims to explore if and how digital health coaching may be used to enhance outcomes for individuals following completion of primary cancer therapy.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Digital Health Coaching Program — Coaching consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
  • Device: Fitbit — Device: Fitbit A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.

Primary Outcomes

  • Acceptability of coaching intervention (At 6 months following the start of the coaching intervention)
  • Feasibility of coaching intervention (At 6 months following the start of the coaching intervention)
  • Change in Self-Efficacy for Managing Chronic Disease (Change in baseline perception of self-efficacy at 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-06-23
Completion: 2027-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 625 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Pack Health
Collaborators: Daiichi Sankyo, GlaxoSmithKline, University of Nebraska, Ohio State University Comprehensive Cancer Center, The University of Texas Health Science Center, Houston, M.D. Anderson Cancer Center, University of Florida, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Gilead Sciences, National Institute of Nursing Research (NINR)
Principal Investigators:
  • Marilyn Hammer, PhD (PRINCIPAL_INVESTIGATOR) - Dana-Farber Cancer Institute
  • Alexi Wright, MD (PRINCIPAL_INVESTIGATOR) - Dana-Farber Cancer Institute
  • Elizabeth Arthur, PhD (PRINCIPAL_INVESTIGATOR) - Ohio State University
Contact Information
Study Contact:
Kelly J Brassil, PhD
205-721-7542
dgxpharesearch@questdiagnostics.com
Jennifer Loftis, DNP
205-721-7542
dgxpharesearch@questdiagnostics.com
Marilyn Hammer, PhD
347-271-0293
marilynj_hammer@dfci.harvard.edu
Dana Farber Cancer Institute
Interventions
  • Behavioral: Digital Health Coaching Program — Coaching consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
  • Device: Fitbit — Device: Fitbit A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
Study Locations (7 sites)
The University of Florida, Gainesville, Florida 32610 United States
Dana Farber Cancer Institute, Boston, Massachusetts 02215 United States
University of Nebraska Medical Center, Omaha, Nebraska 68106 United States
Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States
The Ohio State University Wexner Medical Center, Columbus, Ohio 43210 United States
The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 United States
UT Health Houston, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: 1. Have primary diagnosis of cancer; 2. Are within 1 year of completion of primary therapy OR have a diagnosis of metastatic cancer 1. For the purpose of this study, primary therapy is defined as treatment of curative intent, first-line or later, from which the individual is advancing to active surveillance or follow-up with or without maintenance therapy 2. For individuals with metastatic cancer, individuals may be included provided they completed primary therapy for a de novo diagnosis of metastatic disease within the last year, are within one year of completion of initial therapy for their primary cancer diagnosis for which disease progression has occurred, or who are within one year of receiving treatment for metastatic disease (including individuals currently receiving treatment). 3. Are aged 18 years and older; 4. Can read and consent to participate in the trial; 5. Can read and speak English; 6. Can complete study follow-up at pre-specified intervals; 7. Have access to mobile technology (e.g. a smart phone or tablet) that would allow engagement in digital health coaching for the collection of PROs and wearable data. Exclusion Criteria: 1. Have a cognitive impairment (as assessed by their provider) that would prohibit the individual from engaging with the digital health coaching program or complete study assessments; 2. Have a neurologic, musculoskeletal, or other comorbid condition that would impede their ability to engage in physical activity (as assessed by their provider) 3. Have a life expectancy of \&lt;6 months, and/or 4. Are on active treatment for relapsed disease. a. Individuals with disease progression or relapse which occurs following their consent to participate will be given the option to continue on study if they wish to do so. Data from individuals experiencing disease progression or relapse will be grouped for sub-analysis to explore if and how relapse impacts study outcomes. Healthy Volunteers must: 1. Be adults aged 18 years or older or the age of majority in their state of residence, whichever is older. 2. Must reside in the same dwelling as the patient participant 3. Can read and consent to participate in the trial; 4. Can read and speak English; 5. Can complete study follow-up at pre-specified intervals;
Conditions Triple -Negative Breast Cancertriple, Me...
Phase Not Applicable
Enrollment 32
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

Based on the UPGRADE-TNBC study, a high-quality TNBC sample repository was established. By integrating multi-source data-including clinical information, radiomics, pathological images, and molecular sequencing-and innovatively incorporating a meta-learning strategy, a treatment response prediction model based on multimodal small-sample learning was developed. This approach aims to optimize drug combinations and precisely identify patient subgroups likely to benefit from treatment, thereby providing a new paradigm for personalized therapy in early-stage TNBC.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Interventions / Regimen

  • Other: Collect data — Collect multi-source data from patients, including clinical information, radiomics, pathological images, and molecular sequencing

Primary Outcomes

  • Model building (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-08-06
Completion: 2029-09-01
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 32 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact Information
Study Contact:
Xue Wang
86-010-87787242
wxyxyuki@163.com
Xue Wang
86-010-87787242
wxyxyuki@163.com
Cancer Hospital, Chinese Academy of Medical Sciences
Interventions
  • Other: Collect data — Collect multi-source data from patients, including clinical information, radiomics, pathological images, and molecular sequencing
Study Locations (1 sites)
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality 100021 China
Eligibility Criteria
Inclusion Criteria: * The UPGRADE-TNBC Study Population Exclusion Criteria: * Populations outside the UPGRADE-TNBC study
Conditions HER2-low Hormone Receptor Positive Breas...
Phase PHASE2
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase II Study of HLX22 in Combination with Trastuzumab Deruxtecan (T-DXd) in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients with Disease Progression or Intolerable Adverse Reaction on Standard of Care. Eligible subjects will be treated with the study drug until the loss of clinical benefit, death, intolerable toxicity, withdrawal of informed consent, or other reasons specified by the protocol (whichever occurs first).

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: HLX22 — HLX22 15mg/kg Q3W
  • Drug: Trastuzumab Deruxtecan — Trastuzumab Deruxtecan 5.4mg/kg Q3W

Primary Outcomes

  • Progression-Free Survival (PFS) (Up to 5 years)
  • Objective response rate (ORR) (Up to 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-04-16
Completion: 2029-12-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Henlius Biotech
Contact Information
Study Contact:
Yun Li
+86-15800864157
Shirley_Li@henlius.com
Interventions
  • Drug: HLX22 — HLX22 15mg/kg Q3W
  • Drug: Trastuzumab Deruxtecan — Trastuzumab Deruxtecan 5.4mg/kg Q3W
Study Locations (1 sites)
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality 200000 China
Eligibility Criteria
Inclusion Criteria: 1. Male/female who are at least 18 years of age on the day of signing the informed consent. 2. With histologically confirmed diagnosis of HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer. 3. HER2-low defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested) as assessed by a central laboratory on metastatic tumor and was never previously HER2-positive,and was documented HR+ disease in the metastatic setting 4. Had measurable disease according to the RECIST v1.1, the target lesion must not be a bone metastatic lesion only. 5. ECOG PS: 0-1. 6. Expected survival ≥ 6 months. 7. Had adequate organ function Exclusion Criteria: 1. Patients with other malignant tumors within 3 years before the randomization 2. Previous treatment with any HER2-target therapy 3. Uncontrolled or significant cardiovascular disease or infection 4. Lung-specific intercurrent clinically significant illnesses 5. Prior documented interstitial lung disease (ILD)/ pneumonitis that required steroids, current ILD/ pneumonitis, or suspected ILD/ pneumonitis 6. Patients with spinal cord compression or clinically active central nervous system metastases
Conditions Breast Cancer, Triple Negative Breast Ca...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

This is a single centre Window-of-Opportunity trial investigating the efficacy and feasibility of short term imatinib in patients with newly diagnosed triple negative breast cancer (TNBC) planned for surgery, with tumours ≥ 15 mm, any status in the axilla when neoadjuvant treatment not is considered as an option. The primary aim is to determine the proportion of patients that converts to estrogen receptor (ER) positive breast cancer in the removed breast cancer tissue at surgery.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Drug: Imatinib 400 MG Oral Tablet — One tablet daily 10 days before surgery.

Primary Outcomes

  • To determine the proportion of patients that convert to ER expressing breast cancer (From surgery of the first patient to up to 100 weeks thereafter.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-06-01
Completion: 2029-12-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vastra Gotaland Region
Collaborators: Sahlgrenska University Hospital, Lund University
Principal Investigators:
  • Barbro K Linderholm, MD, PhD (PRINCIPAL_INVESTIGATOR) - Sahlgrenska University Hospital
Contact Information
Study Contact:
Barbro K Linderholm, MD, PhD
+46706045422
barbro.linderholm@oncology.gu.se
Elisabeth Kapocs
+46-31-3420000
elisabeth.kapocs@vgregion.se
Barbro K Linderholm, MD, PhD
+46-31-3420000
barbro.linderholm@oncology.gu.se
Barbro Linderholm
Interventions
  • Drug: Imatinib 400 MG Oral Tablet — One tablet daily 10 days before surgery.
Study Locations (1 sites)
Barbro Linderholm, Gothenburg, 41345 Sweden
Eligibility Criteria
Inclusion Criteria: 1. Histological confirmed invasive primary triple negative breast cancer≥15 mm) with any node status. 2. Age ≥18 years Triple Negative subtype is defined below: 1. Hormone receptor status: the invasive tumour shall be ER- and progesterone receptor (PR) -negative \[staining present in \<10% by immunohistochemistry (IHC)\]. 2. HER2 status: the invasive tumour shall be Human Epidermal growth factor Receptor (HER) 2-negative by the American Society of Clinical Oncology (ASCO) / College of American Pathologists (CAP) guidelines 3. No previous systemic treatment for TNBC 4. No concurrent anti-cancer treatment. Treatment with Bisphosphonates may continue. 5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 6. Normal organ function as defined below: 1. absolute white blood cell count ≥1.5 x 109/L 2. platelets ≥100 x 109/L 3. haemoglobin ≥90g/dL 4. total bilirubin ≤1.5 x institutional upper normal limit (UNL)/dL (≤ 3 x UNL for patients with Gilbert´s syndrome) 5. ASAT, ALAT, GGT and alkaline phosphatase levels \< 1.5 × institutional UNL. 6. albumin \>2.5mg/dL 7. Creatinine \< 110 μmol/L 8. T3, T4 and TSH (only patients with previous thyroid dysfunction) 7. Patients of childbearing potential must have a negative serum or urine pregnancy test within 8 days prior to start of imatinib treatment.. Female patients of childbearing potential must agree to usecontraceptive methods with a failure rate below 1% per year during the study treatment and at least 90 days after the last dose of imatinib. 8. Patients must be able to take (swallow) an oral medication. 9. Patients must be capable to understand and comply with the protocol and has signed the informed consent. Exclusion Criteria: 1. Patients suitable for neoadjuvant treatment. 2. Concomitant treatment for breast cancer within 14 days before registration. 3. Unable to adhere to the study procedures. 4. Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, neurological conditions, physical examination or laboratory findings) that may interfere with the planned treatment or affect patient compliance. 5. Pregnancy and breast-feeding. 6. Concurrent malignancy requiring therapy (excluding non-invasive carcinoma or carcinoma in situ). 7. Known human immunodeficiency virus (HIV) positivity. 8. Known active Hepatitis B or Hepatitis C
Conditions Breast Cancer
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

Breast reconstruction is a critical component of breast cancer treatment because it restores quality of life and body image after mastectomy. However, Spanish-speaking Latina women are significantly less likely to undergo reconstruction (13.5% vs. 41% for non-Latina White or highly acculturated Latina), meet with a reconstructive surgeon (18.1% vs. 72.6% for non-Latina White), or receive adequate information. Spanish-speaking Latina breast cancer survivors who do not have reconstruction experience the highest rates of decisional dissatisfaction and regret, compared to any other group of breast cancer survivors. Persons diagnosed with cancer who primarily speak Spanish and identify as Latin American (hereafter we use the term "Spanish-speaking Latinx/a cancer survivor") are less likely to receive guideline-concordant treatment and more likely to have poor cancer outcomes. One way to improve guideline-concordant treatment is through shared decision-making and decision support. When a decision is preference-sensitive (the right choice depends on the person's preferences), such as decisions about breast reconstruction after mastectomy, decision aids are effective. Unfortunately, most decision aids in the United States are written in English and developed or tested with few Latinx people. The BREASTChoice decision aid, proven effective in two randomized controlled trials, addresses knowledge gaps in breast cancer survivors. This study focuses on developing a Spanish-language version of BREASTChoice, which was previously unavailable. For that reason, the Cultural and Linguistic Adaptation Framework (CLAF) incorporates qualitative and experiential data to adapt BREASTChoice. The adaptation process takes place in five steps: appraise, review, assess, solicit, and integrate.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: Pre-survey — Participants will take a pre-survey to measure demographics, health literacy, numeracy and breast reconstruction decision quality.
  • Behavioral: BREASTChoice tool. — Participants will then engage in a self-guided review of the adapted BREASTChoice tool.
  • Behavioral: Post-survey — Participants will take the post-survey to assess breast reconstruction decision quality.

Primary Outcomes

  • Change in breast reconstruction knowledge (Up to 2 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-10
Completion: 2026-08-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: UNC Lineberger Comprehensive Cancer Center
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Clara Lee, MPP, MD (PRINCIPAL_INVESTIGATOR) - UNC Lineberger Comprehensive Cancer Center
Contact Information
Study Contact:
Victor Catalan Gallegos
+1 919-966-3215
victor.gallegos@med.unc.edu
Meaghan Hazelet
919-966-4320
Meaghan.Hazelet@med.unc.edu
Meaghan Hazelet
919-966-4320
Meaghan.Hazelet@med.unc.edu
The University of North Carolina
Interventions
  • Behavioral: Pre-survey — Participants will take a pre-survey to measure demographics, health literacy, numeracy and breast reconstruction decision quality.
  • Behavioral: BREASTChoice tool. — Participants will then engage in a self-guided review of the adapted BREASTChoice tool.
  • Behavioral: Post-survey — Participants will take the post-survey to assess breast reconstruction decision quality.
Study Locations (1 sites)
The University of North Carolina, Chapel Hill, North Carolina 27599 United States
Eligibility Criteria
Inclusion Criteria for Survivors: (must meet all criteria) * Female sex * Adult at least 18 years of age * Latina, Latino, or Latinx ethnicity - defined as born in or descending from South America, Mexico, Central America, other Spanish-speaking Caribbean islands * Prefer to receive health information in Spanish * Have a history of breast malignancy (e.g., ductal carcinoma, DCIS) or high risk for breast cancer (e.g., BRCA mutation) * Had breast surgery (Mastectomy/Lumpectomy/Mastectomy but no reconstruction) within the last 8 years * Able to understand an IRB-Approved consent information sheet Exclusion Criteria: \-
Conditions Triple Negative Breast Cancer, Breast Ca...
Phase PHASE2
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the study is to evaluate the use of a circulating tumor DNA (ctDNA) assay, ie, a "liquid biopsy," as a tool to identify triple-negative breast cancer (TNBC) patients who will or will not experience benefit from treatment with capecitabine. Participants will be monitored for changes in ctDNA in the blood over time received during capecitabine treatment. Results of ctDNA analysis will be correlated to genetic characteristics of individual tumors. This may inform future clinical trials in which patients could receive a different treatment than capecitabine to reduce their risk of breast cancer relapse.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Capecitabine — 1000 mg/m2 administered on Days 1 to 14 of 21-day treatment cycles, for 8 cycles.

Primary Outcomes

  • Baseline levels of ctDNA detection (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2021-02-03
Completion: 2031-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Stanford University
Principal Investigators:
  • Melinda Telli (PRINCIPAL_INVESTIGATOR) - Stanford Universiy
Contact Information
Study Contact:
Vishal Joshi
650-725-7489
vishalj4@stanford.edu
Vishal Joshi
650-725-7489
vishalj4@stanford.edu
Stanford University
Melinda Telli, MD
Stanford University
Interventions
  • Drug: Capecitabine — 1000 mg/m2 administered on Days 1 to 14 of 21-day treatment cycles, for 8 cycles.
Study Locations (1 sites)
Stanford University, Stanford, California 94304 United States
Eligibility Criteria
Inclusion Criteria: 1. Anatomic stage I - III triple-negative breast cancer at diagnosis 2. Estrogen receptors (ER) and Progesterone receptors (PR) status \<10% 3. Residual disease following at least 4 cycles of neoadjuvant chemotherapy. Patients who received other investigational immunotherapy or targeted therapy during the neoadjuvant phase of treatment are eligible. 4. ≥ 18 years of age 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 6. All clinically significant toxic effects of prior cancer therapy resolved to Grade ≤ 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE, v 5.0), except alopecia and G2 neuropathy. 7. No evidence of metastatic disease. 8. A minimum 4-week wash out from previous chemotherapy treatment is required. 9. Adequate hematologic function: Absolute neutrophil count (ANC) ≥ 1,500 cells/μL (≥ 1,500/mm3); Platelets ≥ 100,000 cells/μL (≥ 100,000/mm3) 10. Adequate hepatic function: Bilirubin ≤ 1.5 times the specific institutional upper limit of normal (ULN). Exception: If Gilbert's syndrome; then ≤ 5 times ULN. Aspartate transaminase (AST) and alanine transaminase (ALT) each ≤ 2.5 x ULN 11. Adequate renal function: Serum creatinine ≤ 1.5 x ULN; or calculated creatinine clearance \> 50 mL/min using the Cockcroft Gault formula. 12. Planned for 6 months or 8 cycles of adjuvant capecitabine. 13. Women of childbearing potential (WOCBP) must have a negative pregnancy test. 14. WOCBP must agree to use effective contraception during the study and for 3 months after the last dose. 15. Male participants and their female partners of child bearing potential must be willing to use an appropriate method of contraception during the study and for 3 months after the last dose. 16. Capable of giving signed informed consent, which includes compliance with requirements and restrictions listed in the informed consent form (ICF) and in the protocol Exclusion Criteria: 1. Metastatic breast cancer 2. Has not had definitive surgical resection 3. Pregnant or breastfeeding 4. Has not completed definitive adjuvant radiation if planned 5. Known human immunodeficiency virus (HIV) positivity or active hepatitis B or C. 6. Investigational agents within 4 weeks of study initiation 7. Inability to swallow oral medications
Conditions Sensation Disorder
Phase Not Applicable
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this comparative study is to learn how different surgical methods affect nipple and skin sensation after nipple-sparing mastectomy (NSM). The study will compare three types of NSM: conventional, endoscopic, and robotic. The main question it aims to answer is: How much nipple sensation do participants keep after each type of surgery? Researchers will also look at surgery-related complications, patient-reported outcomes like body image and quality of life, and tissue analysis to see if there is a link between nerve structures and sensation. Participants will: Have NSM using one of the three surgical approaches Receive breast reconstruction with an implant during the same surgery Complete nipple sensation tests before and at 1, 3, and 6 months after surgery Answer surveys about their quality of life and body image Provide surgical tissue for analysis (as part of the planned procedure)

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Nipple Sensation Assessment — the measurement of nipple sensation preservation, will be conducted using the Semmes-Weinstein esthesiometer. The clinician will use the device to touch the nipple and the surrounding quadrants of the skin, applying filaments of increasing calibers (0.07gr, 0.4gr, 2.0gr, 4.0gr, 300gr), and the lightest caliber perceived by the patient will be recorded. This assessment will be conducted at four different times: * Before surgery, to assess baseline sensation. * 1 month after surgery. * 3 months after surgery. * 6 months after surgery.

Primary Outcomes

  • measurement of nipple sensation preservation (This assessment will be conducted at four different times: • Before surgery, to assess baseline sensation. • 1 month after surgery. • 3 months after surgery. • 6 months after surgery.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-06-01
Completion: 2027-12-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Candiolo Cancer Institute - IRCCS
Principal Investigators:
  • Giada Pozzi, MD (PRINCIPAL_INVESTIGATOR) - Candiolo Cancer Institute FPO-IRCCS
Contact Information
Study Contact:
Giada Pozzi, MD
+39 011 9933017
giada.pozzi@ircc.it
Candiolo Cancer Institute FPO-IRCCS
+39 0119933111
social@ircc.it
Candiolo Cancer Institute FPO-IRCCS
Interventions
  • Diagnostic Test: Nipple Sensation Assessment — the measurement of nipple sensation preservation, will be conducted using the Semmes-Weinstein esthesiometer. The clinician will use the device to touch the nipple and the surrounding quadrants of the skin, applying filaments of increasing calibers (0.07gr, 0.4gr, 2.0gr, 4.0gr, 300gr), and the lightest caliber perceived by the patient will be recorded. This assessment will be conducted at four different times: * Before surgery, to assess baseline sensation. * 1 month after surgery. * 3 months after surgery. * 6 months after surgery.
Study Locations (1 sites)
Candiolo Cancer Institute FPO-IRCCS, Torino, 10060 Italy
Eligibility Criteria
Inclusion Criteria: * Female patients aged ≥18 years. * Diagnosed with early-stage breast cancer or deemed at high risk for breast cancer (eg. BRCA1-2 mutations). * Candidates for Nipple-Sparing Mastectomy (NSM). * Able to provide informed consent. * No contraindications for surgery based on physical examination and preoperative assessment. * Signed the consent forms and willing to participate in all scheduled follow-up assessments. Exclusion Criteria: * Previous breast surgery. * History of radiation therapy to the chest/breast area. * Active or non-controlled diabetes mellitus. * Neuropathies causing potentially altered skin sensation. * Nipple involvement by cancer, clinical or reported intra-operatively via frozen section analysis (the procedure will be converted to SSM).